Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo, Takeda Reach Second Collaboration

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies today announced a second collaboration with Takeda Pharmaceuticals to use its technology to assist in the development of drugs.

Under the agreement, German firm Kinaxo will employ its quantitative phosphoproteomics technology, PhosphoScout, in the research, allowing Takeda to make early educated decisions on drug efficacy and safety, Kinaxo said. PhosphoScout uses mass spectrometry methods to enable unbiased quantification of about 15,000 phosphorylation sites in one experiment.

Financial and other terms of the deal were not disclosed.

Kinaxo and Takeda inked an agreement in 2008 for use of Kinaxo's KinaTor chemical proteomics technology.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.